Legend Biotech/LEGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Legend Biotech

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Ticker

LEGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ying Huang

Employees

1,800

Headquarters

Somerset, United States

Legend Biotech Metrics

BasicAdvanced
$7.3B
Market cap
-
P/E ratio
-$2.60
EPS
0.09
Beta
-
Dividend rate
$7.3B
0.09307
$77.32
$39.13
1.1M
5.663
5.574
28.484
28.752
-24.44%
-31.22%
-51.28%
-37.33%
21.275
6.265
6.282
231.84%
20.52%
56.08%

What the Analysts think about Legend Biotech

Analyst Ratings

Majority rating from 22 analysts.
Buy

Legend Biotech Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-63.57% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$94M
18.26%
Net income
-$60M
-58.77%
Profit margin
-63.57%
-65.14%

Legend Biotech Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.05%
QuarterlyAnnual
Q3 22
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-
-$1.14
-$0.34
-$0.80
-$0.32
Expected
-$0.40
-$0.60
-$0.68
-$0.83
-$0.34
Surprise
-
90.00%
-49.82%
-3.61%
-7.05%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractionalADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Legend Biotech stock?

Legend Biotech (LEGN) has a market cap of $7.3B as of June 20, 2024.

What is the P/E ratio for Legend Biotech stock?

The price to earnings (P/E) ratio for Legend Biotech (LEGN) stock is 0 as of June 20, 2024.

Does Legend Biotech stock pay dividends?

No, Legend Biotech (LEGN) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Legend Biotech dividend payment date?

Legend Biotech (LEGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Legend Biotech?

Legend Biotech (LEGN) has a beta rating of 0.09. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Legend Biotech stock price target?

The target price for Legend Biotech (LEGN) stock is $83.45, which is NaN% below the current price of $. This is an average based on projections from 19 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Legend Biotech stock

Buy or sell Legend Biotech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing